ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction
Cells · 2025
DOI: 10.3390/cells14181411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Michael Holzer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otto-Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Platelet Activation, Platelet Glycoprotein GPIIb-IIIa Complex. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund, Austrian Science Fund (FWF), Franz Lanyar-Stifung.
Abstract (Originalsprache)
Apolipoprotein C3 (apoC3) is a key regulator of triglyceride metabolism and has emerged as a potential therapeutic target for reducing the risk of cardiovascular disease. However, its broader physiological functions are not fully understood. This study investigates the role of apoC3 in platelet function and thrombus formation. Interestingly, human apoC3 was found to rapidly inhibit platelet activation over the tested concentration range of 0.1–10 µg/mL, with significant effects observed at low concentrations and brief pre-incubation times (from 1 min). At a concentration of 10 µg/mL, apoC3 suppressed platelet activation by approximately 70% in response to ADP and by approximately 40% in response to collagen stimulation. Depleting apoC3 from human serum enhanced platelet aggregation by more than 25 % (1.28 ± 0.19 vs. vehicle), indicating an endogenous regulatory function of apoC3. Mechanistically, apoC3 binding to platelets reduced both GPIIb/IIIa activation and P-selectin expression by around 20%. ApoC3 binding to platelets increased when platelets were activated by ADP and was partially mediated by GPIIb/IIIa, implicating this integrin as a functionally relevant receptor. Taken together, these findings reveal a novel link between apoC3 and platelet biology with potential implications for thrombotic risk and vascular homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otto-Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria.
- BioTechMed-Graz, 8010 Graz, Austria.
- Division of Haematology, Medical University of Graz, 8010 Graz, Austria.
- Division of Medical Physics and Biophysics, Gottfried Schatz Research Center, Medical University of Graz, 8010 Graz, Austria.
- Division of Medicinal Chemistry, Otto-Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.
ORCID-Profile: Michael Holzer, Eva Gruden, Gerhard Cvirn, Gunther Marsche
Förderung
- FWF Austrian Science Fund
- Austrian Science Fund (FWF)
- Franz Lanyar-Stifung
Zitieren
APA
Holzer, M., Gruden, E., Curcic, S., Cvirn, G., & Marsche, G. (2025). ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction. Cells. https://doi.org/10.3390/cells14181411
Vancouver
Holzer M, Gruden E, Curcic S, Cvirn G, Marsche G. ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction. Cells. 2025. doi:10.3390/cells14181411
BibTeX
@article{Holzer2025,
author = {Holzer, Michael and Gruden, Eva and Curcic, Sanja and Cvirn, Gerhard and Marsche, Gunther},
title = {ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14181411}
}
EUVIMED